Publications

• 2009 Guidelines
• 2007 Guidelines
  • Table of Contents
  • Introduction and purposes
• Hypertension Guidelines
  • Guidelines Critisism
  • Publication 2
• Studies
  • 24hours Blood Pressure
  • CHARM benefit regardless ACE dose
  • Exercise Exaggerated BP Response
  • STAR Study
  • Trophy Study
  • Controled Clinical Trials
  • Blood Pressure Reduction
  • Is New-Onset Diabetes of Clinical Significance in Treated Patients?
  • ARAMIS Study
  • Messages from Treatment Trials
  • CAMELOT: Study Design
  • INVEST
  • Overview ACTION
• Medicines
  • Publication 1
  • Publication 2
  • ESPRIT
  • b Blockers
  • PPARγ Activating Angiotensin Type-1 Receptor Blockers
  • Sartans & PPRAγ Benson
• Metabolic Syndrome
  • MCEX-Nagel - Telmisartan
  • Presioni Arteriose Monitorate
  • Insulin Sensitizing Effects of Telmisartan
  • New Treatment Strategies
  • Treating the metabolic syndrome
  • Antidiabetic mechanisms
  • Ramipril vs Telmisartan
  • Angiotensin Type 1 Receptor Blockers
  • Telmisartan: PPARγ Activation & Metabolic Effects
  • PPAR Ligands: Potential Therapies
  • Metabolic Syndrome and type 2 diabetes mellitus
  • Tsai Y-S 2004
• Όργανα Στόχοι
  • Beta Blockers
  • Telmi vs Enalapril
  • Vascular Protection in Diabetes
• Cardiovascular Disease
  • Action HF paper
  • McMurrey AHJ
  • Remaining Issues
  • Telmi vs Valsa
  • A cure for Cardiovascular disease?
  • A Strategy to reduce cardiovascular disease
  • Polypill for Cardiovascular Disease Prevention
  • Polypill to fight cardiovascular disease
  • Polypill to fight cardiovascular disease - Response
  • Poly-Portfolio
  • Take forward the polypill idea
  • The Polymeal
  • Polypill - Not for primary prevention
  • PPRAγ Roberts AW
• Other
  • Renal Complications in diabetic patients
  • Exercise Capacity 24h BP
  • Exercise Capacity & Blood Pressure
  • IJC Replace
  • Neldam
  • ASCOT Trial
  • The Year in Hypertension 2006
  • Value of low dose compination
  • PPRAγ Berger J.P.